Notch receptors in human choroid plexus tumors

Histology and Histopathology

Volumn 28, Issue 8, 2013, Pages 1055-1063

  Beschorner, Rudi ^a   Waidelich, J ^a   Trautmann, K ^a   Psaras, T ^a   Schittenhelm, J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Choroid plexus tumor; Chroid plexus epithelium; Her2; Notch receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOPSY; BRAIN; CARCINOMA; CHILD; CHOROID PLEXUS; CHOROID PLEXUS CARCINOMA; CHOROID PLEXUS TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; METABOLISM; MIDDLE AGED; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOPSY; BRAIN; CARCINOMA; CHILD; CHILD, PRESCHOOL; CHOROID PLEXUS; CHOROID PLEXUS NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, NOTCH; YOUNG ADULT;

EID: 84880435220     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Beschorner R., Pantazis G., Jeibmann A., Boy J., Meyermann R., Mittelbronn M. and Schittenhelm J. (2009). Expression of EAAT-1 distinguishes choroid plexus tumors from normal and reactive choroid plexus epithelium. Acta Neuropathol. 117, 667-675.
2. Bin H.B., Adhami V.M., Asim M., Siddiqui I.A., Bhat K.M., Zhong W., Saleem M., Din M., Setaluri V. and Mukhtar H. (2009). Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin. Cancer Res. 15, 452-459.
3. Calicchio M.L., Collins T. and Kozakewich H.P. (2009). Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am. J. Pathol. 174, 1638-1649.
4. Callahan R. and Egan S.E. (2004). Notch signaling in mammary development and oncogenesis. J. Mammary Gland. Biol. Neoplasia 9, 145-163.
5. Cobellis L., Caprio F., Trabucco E., Mastrogiacomo A., Coppola G., Manente L., Colacurci N., De F.M. and De L.A. (2008). The pattern of expression of Notch protein members in normal and pathological endometrium. J. Anat. 213, 464-472.
6. Dang L., Fan X., Chaudhry A., Wang M., Gaiano N. and Eberhart C.G. (2006). Notch3 signaling initiates choroid plexus tumor formation. Oncogene 25, 487-491.
7. Everitt B.S. (1996). Making sense of statistics in psychology: A secondlevel course. Oxford University Press. New York, USA.
8. Florena A.M., Tripodo C., Guarnotta C., Ingrao S., Porcasi R., Martorana A., Lo B.G., Cabibi D. and Franco V. (2007). Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. Pathobiology 74, 317-322.
9. Fouladi M., Stewart C.F., Olson J., Wagner L.M., Onar-Thomas A., Kocak M., Packer R.J., Goldman S., Gururangan S., Gajjar A., Demuth T., Kun L.E., Boyett J.M. and Gilbertson R.J. (2011). Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J. Clin. Oncol. 29, 3529-3534.
10. Gao J., Song Z., Chen Y., Xia L., Wang J., Fan R., Du R., Zhang F., Hong L., Song J., Zou X., Xu H., Zheng G., Liu J. and Fan D. (2008). Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig. Liver Dis. 40, 114-121.
11. Garcia A. and Kandel J.J. (2012). Notch: a key regulator of tumor angiogenesis and metastasis. Histol. Histopathol. 27, 151-156.
12. Gridley T. (2010). Notch signaling in the vasculature. Curr. Top. Dev. Biol 92, 277-309.
13. Higuchi M., Kiyama H., Hayakawa T., Hamada Y. and Tsujimoto Y. (1995). Differential expression of Notch1 and Notch2 in developing and adult mouse brain. Brain Res. Mol. Brain Res. 29, 263-272.
14. Irvin D.K., Zurcher S.D., Nguyen T., Weinmaster G. and Kornblum H.I. (2001). Expression patterns of Notch1, Notch2, and Notch3 suggest multiple functional roles for the Notch-DSL signaling system during brain development. J. Comp Neurol. 436, 167-181.
15. Joutel A., Favrole P., Labauge P., Chabriat H., Lescoat C., Andreux F., Domenga V., Cecillon M., Vahedi K., Ducros A., Cave-Riant F., Bousser M.G. and Tournier-Lasserve E. (2001). Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet 358, 2049-2051.
16. Joutel A., Monet-Lepretre M., Gosele C., Baron-Menguy C., Hammes A., Schmidt S., Lemaire-Carrette B., Domenga V., Schedl A., Lacombe P. and Hubner N. (2010). Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J. Clin. Invest 120, 433-445.
17. Kopan R. and Ilagan M.X. (2009). The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233.
18. Leong K.G. and Karsan A. (2006). Recent insights into the role of Notch signaling in tumorigenesis. Blood 107, 2223-2233.
19. Lewandowska E., Szpak G.M., Wierzba-Bobrowicz T., Modzelewska J., Stepien T., Pasennik E., Schmidt-Sidor B. and Rafalowska J. (2010). Capillary vessel wall in CADASIL angiopathy. Folia Neuropathol. 48, 104-115.
20. Lindsay J., Jiao X., Sakamaki T., Casimiro M.C., Shirley L.A., Tran T.H., Ju X., Liu M., Li Z., Wang C., Katiyar S., Rao M., Allen K.G., Glazer R.I., Ge C., Stanley P., Lisanti M.P., Rui H. and Pestell R.G. (2008). ErbB2 induces Notch1 activity and function in breast cancer cells. Clin. Transl. Sci. 1, 107-115.
21. Lindsell C.E., Boulter J., Di Sibio G., Gossler A. and Weinmaster G. (1996). Expression patterns of Jagged, Delta1, Notch1, Notch2, and Notch3 genes identify ligand-receptor pairs that may function in neural development. Mol. Cell Neurosci. 8, 14-27.
22. Magnifico A., Albano L., Campaner S., Delia D., Castiglioni F., Gasparini P., Sozzi G., Fontanella E., Menard S. and Tagliabue E. (2009). Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 15, 2010-2021.
23. Malinge S. and Crispino J. (2010). Notch: of mice and men? Blood 116, 5438-5439.
24. Merrill M.J., Edwards N.A. and Lonser R.R. (2011). Notch receptor and effector expression in von Hippel-Lindau disease-associated central nervous system hemangioblastomas. J. Neurosurg. 115, 512-517.
25. Milde T., Hielscher T., Witt H., Kool M., Mack S.C., Deubzer H.E., Oehme I., Lodrini M., Benner A., Taylor M.D., von D.A., Kulozik A.E., Pfister S.M., Witt O. and Korshunov A. (2012). Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol. 22, 848-860.
26. Mumm J.S. and Kopan R. (2000). Notch signaling: from the outside in. Dev. Biol 228, 151-165.
27. +-ATPase. Biochem. J. 342 (Pt 2), 329-336.
28. O'Neill C.F., Urs S., Cinelli C., Lincoln A., Nadeau R.J., Leon R., Toher J., Mouta-Bellum C., Friesel R.E. and Liaw L. (2007). Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am. J. Pathol. 171, 1023-1036.
29. Osipo C., Patel P., Rizzo P., Clementz A.G., Hao L., Golde T.E. and Miele L. (2008). ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27, 5019-5032.
30. Perumalsamy L.R., Nagala M., Banerjee P. and Sarin A. (2009). A hierarchical cascade activated by non-canonical Notch signaling and the mTOR-Rictor complex regulates neglect-induced death in mammalian cells. Cell Death. Differ. 16, 879-889.
31. Pierfelice T.J., Schreck K.C., Dang L., Asnaghi L., Gaiano N. and Eberhart C.G. (2011). Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res. 71, 1115-1125.
32. Pradeep C.R., Kostler W.J., Lauriola M., Granit R.Z., Zhang F., Jacob-Hirsch J., Rechavi G., Nair H.B., Hennessy B.T., Gonzalez-Angulo A.M., Tekmal R.R., Ben-Porath I., Mills G.B., Domany E. and Yarden Y. (2012). Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 31, 907-917.
33. Puget S., Grill J., Valent A., Bieche I., ntas-Barbosa C., Kauffmann A., Dessen P., Lacroix L., Geoerger B., Job B., Dirven C., Varlet P., Peyre M., Dirks P.B., Sainte-Rose C. and Vassal G. (2009). Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J. Clin. Oncol. 27, 1884-1892.
34. Purow B.W., Haque R.M., Noel M.W., Su Q., Burdick M.J., Lee J., Sundaresan T., Pastorino S., Park J.K., Mikolaenko I., Maric D., Eberhart C.G. and Fine H.A. (2005). Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 65, 2353-2363.
35. Rafalowska J., Fidzianska A., Dziewulska D., Podlecka A., Szpak G.M. and Kwiecinski H. (2003). CADASIL: new cases and new questions. Acta Neuropathol. 106, 569-574.
36. Rafalowska J., Fidzianska A., Dziewulska D., Podlecka A., Szpak G.M. and Kwiecinski H. (2004). CADASIL or CADVaSIL? Neuropathology 24, 16-20.
37. Rizzo P., Osipo C., Foreman K., Golde T., Osborne B. and Miele L. (2008). Rational targeting of Notch signaling in cancer. Oncogene 27, 5124-5131.
38. Saiki S., Sakai K., Saiki M., Kitagawa Y., Umemori T., Murata K., Matsui M. and Hirose G. (2006). Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene. Neurology 67, 337-339.
39. Serafin V., Persano L., Moserle L., Esposito G., Ghisi M., Curtarello M., Bonanno L., Masiero M., Ribatti D., Sturzl M., Naschberger E., Croner R.S., Jubb A.M., Harris A.L., Koeppen H., Amadori A. and Indraccolo S. (2011). Notch3 signalling promotes tumour growth in colorectal cancer. J. Pathol. 224, 448-460.
40. Sharma A., Paranjape A.N., Rangarajan A. and Dighe R.R. (2012). A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells. Mol. Cancer Ther. 11, 77-86.
41. Siar C.H., Nakano K., Han P.P., Nagatsuka H., Ng K.H. and Kawakami T. (2010). Differential expression of Notch receptors and their ligands in desmoplastic ameloblastoma. J. Oral Pathol. Med. 39, 552-558.
42. Srivastava S., Ramdass B., Nagarajan S., Rehman M., Mukherjee G. and Krishna S. (2010). Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. Br. J. Cancer 102, 196-205.
43. Stevens J.P. (1999). Intermediate statistics. A modern approach. Lawrence Erlbaum Associates, Inc. London.
44. Strosberg J.R., Yeatman T., Weber J., Coppola D., Schell M.J., Han G., Almhanna K., Kim R., Valone T., Jump H. and Sullivan D. (2012). A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer 48, 997-1003.
45. Tolcher A.W., Messersmith W.A., Mikulski S.M., Papadopoulos K.P., Kwak E.L., Gibbon D.G., Patnaik A., Falchook G.S., Dasari A., Shapiro G.I., Boylan J.F., Xu Z.X., Wang K., Koehler A., Song J., Middleton S.A., Deutsch J., Demario M., Kurzrock R. and Wheler J.J. (2012). Phase I study of RO4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348-2353.
46. Weinmaster G., Roberts V.J. and Lemke G. (1992). Notch2: a second mammalian Notch gene. Development 116, 931-941.
47. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., Chen Y., Finkle D., Venook R., Wu X., Ridgway J., Schahin-Reed D., Dow G.J., Shelton A., Stawicki S., Watts R.J., Zhang J., Choy R., Howard P., Kadyk L., Yan M., Zha J., Callahan C.A., Hymowitz S.G. and Siebel C.W. (2010). Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052-1057.
48. Xu P., Yu S., Jiang R., Kang C., Wang G., Jiang H. and Pu P. (2009). Differential expression of Notch family members in astrocytomas and medulloblastomas. Pathol. Oncol. Res. 15, 703-710.
49. Yoon H.A., Noh M.H., Kim B.G., Han J.S., Jang J.S., Choi S.R., Jeong J.S. and Chun J.H. (2011). Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J. Gastroenterol. 17, 4023-4030.
50. Zardawi S.J., O'Toole S.A., Sutherland R.L. and Musgrove E.A. (2009). Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol. Histopathol. 24, 385-398.